|
gptkbp:instanceOf
|
gptkb:drug
immunomodulatory drug
thalidomide derivative
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AX04
|
|
gptkbp:brand
|
gptkb:Revlimid
|
|
gptkbp:CASNumber
|
191732-72-6
|
|
gptkbp:category
|
antineoplastic agent
immunosuppressant
|
|
gptkbp:chemicalFormula
|
C13H13N3O3
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
gptkb:Celgene
|
|
gptkbp:eliminationHalfLife
|
3-5 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lenalidomide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
induces apoptosis in cancer cells
modulates immune system
inhibits angiogenesis
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
259.26 g/mol
|
|
gptkbp:monitors
|
complete blood count
pregnancy test
|
|
gptkbp:patentExpired
|
2022 (US)
|
|
gptkbp:pregnancyCategory
|
X (contraindicated)
|
|
gptkbp:prescribingProgram
|
gptkb:REMS_(Risk_Evaluation_and_Mitigation_Strategy)
|
|
gptkbp:relatedTo
|
gptkb:thalidomide
gptkb:pomalidomide
|
|
gptkbp:riskFactor
|
teratogenicity
secondary malignancies
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
increased risk of blood clots
rash
neutropenia
thrombocytopenia
|
|
gptkbp:usedFor
|
gptkb:mantle_cell_lymphoma
multiple myeloma
diffuse large B-cell lymphoma
myelodysplastic syndromes
follicular lymphoma
|
|
gptkbp:bfsParent
|
gptkb:Celgene
gptkb:Monjuvi
gptkb:Tafasitamab
gptkb:Darzalex
|
|
gptkbp:bfsLayer
|
6
|